Offline Website MakerI am a former professor of clinical medicine at University College London, UK. I trained as a clinical academic endocrinologist and over 3 decades developed multidisciplinary obesity services at Guy’s, Luton, Cambridge, and University College London hospitals in England. From 2016-2022, I was Senior Principal Clinical Scientist, Global Medical Affairs, with Novo Nordisk in Denmark. My research on obesity and its related complications is represented by 200 peer-reviewed papers and reviews, and more than 23 book chapters as well as extensive invitations to lecture. I was past Chair of the UK Association for the Study of Obesity and World Obesity Federation Clinical Care, where amongst other roles I was responsible for developing the SCOPE educational programme; I have held positions with the UK Government Advisory Group on Obesity, National Institute for Health and Care Excellence Public Health Advisory Group, European Association for the Study of Obesity, and the European Society of Hypertension. I received the Bisset Hawkins Medal, a triennial award 'for … promoting public health', and in 2024 the Willendorf Prize from the World Obesity Federation.I was the founding Editor-in-Chief of Clinical Obesity from 2011-2022, and am an elected fellow of the Royal College of Physicians, the US Obesity Society, and the UK Association for Nutrition.
1. Kopelman PG, Finer N, White N, Jeffcoate SL (1983). Impaired hypothalamic control of prolactin secretion in obesity. Journal of Obesity and Weight Regulation 1983; 2:162 180.
2. Jones N, Finer N. Spontaneous resolution of acromegaly and development of "empty sella syndrome" following gastro-intestinal haemorrhage. British Medical Journal 1984; 289:661.
3. of infertility. Acta Endocrinologica 1984; 107: 439 444.
4. Finer N, Emery P, Hicks BH. Mammary gigantism and d penicillamine. Clinical Endocrinology 1984;21:219 22.
5. Finer N, Swan PC, Mitchell FT. Hypothalamic function and energy output in obesity. Journal of Obesity and Weight Regulation 1985; 4:87 97.
6. Finer N. Do frequent visits improve diabetic control? Practical Diabetes 1985: 2;30 31.
7. Finer N, Fogelman I. Pregnancy in a woman with premature ovarian failure. Postgraduate Medical Journal 1985; 61:1079 1080.
8. Finer N, Swan PC, Mitchell FT. Suppression of norepinephrine induced thermogenesis in human obesity by diet and weight loss. International Journal of Obesity 1985; 9: 121 126.
9. Finer N, Swan PC, Mitchell FT. Metabolic rate after massive weight loss in human obesity. Clinical Science 1986; 70: 395-398.
10. Lieberman HR, Caballero B, Finer N. The composition of lunch determines afternoon plasma tryptophan ratios in humans. Journal of Neural Transmission 1986;65: 211-217.
11. Caballero, B., Finer, N., and Wurtman, R.J. Plasma amino acid levels in obesity: Effects of insulin resistance. In: Amino Acids in Health and Diseases: New Perspectives (S. Kaufman, ed.) Alan R. Liss, Inc., New York, pp.369-382, 1987
12. Finer N, Price P, Grossman A, Besser GM. The effect of enkephalin analogue on pituitary hormone release in massive human obesity. Hormone & Metabolic Research 1986;19: 68-70.
13. Nussey SS, Ang VY, Finer N, Jenkins JS. Responses of neurohypophysial peptides to hypertonic saline and insulin-induced hypoglycaemia in Man. Clinical Endocrinology 1986; 24: 97-105.
14. Finer N, Craddock D, Lavielle R, Keen H. Prolonged weight loss with dexfenfluramine treatment in obese patients. Diabète et Métabolisme 1987;13: 598-602.
15. Finer N, Craddock D, Lavielle R, Keen H. Effect of six months therapy with dexfenfluramine in obese patients: studies in the United Kingdom. Clinical Neuropharmacology 1988;11 Suppl. 1: S179-186.
16. Ponder BAJ and the Cancer Research Campaign Medullary Thyroid Group. Risk estimation and screening in families of patients with medullary thyroid carcinoma. Lancet 1988;1: 397-401.
17. Ponder BAJ, Finer N, Coffey R, Maisey M et al. Family screening in medullary thyroid carcinoma presenting without a family history. Quarterly Journal of Medicine 1988; 67(1):299-308.
18. Caballero B, Finer N, Wurtman RJ. Plasma amino acids and insulin levels in obesity: response to carbohydrate intake and tryptophan supplements. Metabolism 1988; 37: 672-66.
19. Finer N, Finer S, Naoumova RP. Prolonged use of a very low-calorie diet in massively obese patients attending an obesity clinic: safety, efficacy and additional benefit from dexfenfluramine. International Journal of Obesity 1989;13 (Suppl. 2):91-93.
20. Finer N. Serotoninergic system: therapeutic implications in obesity. Acta Clinica Belgica 1992;47 (Suppl. 14):47-51.
21. Finer N, Finer S, Naoumova RP. Drug therapy after very low-calorie diets. American Journal of Clinical Nutrition 1992; 56: 195S -198S.
22. Finer N and Goustas P. Ceftazidime versus aminoglycoside and (ureido)penicillin in the empirical treatment of serious infection. Journal of the Royal Society of Medicine 1992;85: 530-34.
23. Finer N. Body weight evolution during dexfenfluramine treatment after initial weight control. International Journal of Obesity 1992;16(Supplement 3): S25-30.
24. Report on the NIH Workshop on Pharmacologic Treatment of Obesity. American Journal of Clinical Nutrition 1994; 60: 153-6.
25. Kopelman PG, Finer N, Fox KR, Hill A, MacDonald IA. ASO Consensus Statement on Obesity. International Journal of Obesity 1994;18:189-191.
26. Roberts GA, Eren E, Pelling M, Burns A, Bradford R, Maurice-Williams R, Black CM, Finer N, Bouloux P-M G. Two cases of Wegener’s granulomatosis involving the pituitary. Clinical Endocrinology 1995; 42: 323-328.
27. Draeger KE, Wernicke-Panten K, Lomp H-J, Schuler E, Rosskamp R and Glimepiride Multicentre Study Group. Long-term treatment of Type 2 diabetic patients with the new oral antidiabetic agent glimepiride (Amaryl): a double-blind comparison with glibenclamide. Hormone and Metabolic Research 1996; 28: 419-25.
28. Van Gaal LF, Broom JI, Enzi G, Toplak H, and the Orlistat Dose Ranging Study Group. Efficacy and tolerability of orlistat in the treatment of obesity: a 6-month dose-ranging study. European Journal of Clinical Pharmacology 1998; 54: 125-132.
29. P. Barrett, N. Finer, C. Fisher, G. Boyle. Evaluation of a multi-modality treatment programme for weight management at the Luton and Dunstable Hospital NHS Trust. Journal of Human Nutrition & Dietetics 1999;12 Suppl. 1:43-52.
30. Finer N, James WPT, Kopelman PG, Lean MEJ, Williams G. One-year treatment of obesity: a randomised, double-blind, placebo-controlled, multicentre study of orlistat (Xenical), a gastrointestinal lipase inhibitor. International Journal of Obesity 2000; 24: 306-13.
31. D Hughes, McGuire A, Elliot H, Finer N, Lean MEJ, Prentice AM, Ritchie L The cost of obesity in the United Kingdom. Journal of Medical Economics 1999; 2: 143-153
32. Finer N, Bloom SR, Griffiths J, Jones SP, Romanec FM. A randomised, placebo-controlled trial of the effects of sibutramine 15 mg once daily on body weight and symptoms of diabetes in obese subjects with non-insulin-dependent diabetes mellitus. Diabetes, Obesity & Metabolism 2000;2(2):105-112
33. Finer, N., Marti, A., Williams, G., Harrold, J. A., & Cutler, D. J. (2000). University of Navarra, Pamplona, Spain, 8-11 September 1999-Symposium on 'Signalling in body-weight homeostasis'-The hypothalamus and the regulation of energy homeostasis: Lifting the lid on a. Proceedings of the Nutrition Society, 59 (3), 385-396
34. Gibney, M. J., Martinez, J. A., & Finer, N. (2000). University of Navarra, Pamplona, Spain, 8-11 September 1999-Videoconference on 'Management of obesity'-Prevention and management of obesity: Pharmacology. Proceedings of the Nutrition Society, 59 (3), 413-414
35. Astrup A & Finer N. Redefining Type 2 diabetes: ‘diabesity’ or ‘Obesity Dependent Diabetes Mellitus’? Obesity Reviews 2000;1:
36. Astrup A, Madsbad S, Finer N. Ny viden on arsag til diabetes: Type 2 diabetes til adipositas-dependent diabetes mellitus. Journal of the Danish Medical Association 2000;
37. Finer N. Prevention and Management of Obesity. Proceedings of the Nutrition Society 2000; 59:413
38. WT James, Astrup A, Finer N et al. Effect of sibutramine on weight loss maintenance after weight loss: a randomised trial. Lancet 2001;356(9248):2119-25
39. Hansen,DL, Astrup A, Toubro S, Finer, N, Kopelman P, Hilsted J et al. Predictors of weight loss and maintenance during 2 years treatment by sibutramine in obesity. Results from the European multi-centre STORM trial. International Journal of Obesity 2001;25(4):496-501
40. James WPT, Astrup A, Finer N on behalf of the STORM group. Drug therapy for management of obesity. Lancet 2001; 357: 1288 (letter)
41. Kopelman PG, Finer N. Is obesity a disease? International Journal of Obesity 2001; 25 (10):1405-6.
42. Finer N. Sibutramine in clinical practice. International Journal of Obesity 2001; 25 (Suppl. 4):S12-S15
43. James WPT and Finer N. The role of sibutramine in weight management – towards a blueprint for a sibutramine weight management system. International Journal of Obesity 2001;25 (Suppl. 4):S34-S38
44. Finer N. Low-calorie diets and sustained weight loss. Obes Res. 2001;9 Suppl. 4:290S-294S
45. Kong WM, Sheikh M, Lumb P, Naoumova R, Freedman D, Crook M, Dore CJ, Finer N. A six-month randomised trial of thyroxine treatment in mild subclinical hypothyroidism in women. The American Journal of Medicine 2002; 112(5): 348-354
46. Pakianathan IC, Sheikh M, Feben S, Finer N. The eating disorder inventory in a UK National Health Service Clinic and its response to modest weight loss. Eating Behaviors 2002; 3:275-284
47. Krebs JD, Evans S, Cooney L, Mishra GD, Fruhbeck G, Finer N, Jebb SA. Changes in risk factors for cardiovascular disease with body fat loss in obese women. Diabetes, Obesity and Metabolism 2002;4(6):379-387
48. Finer N. Sibutramine: its mode of action and efficacy. Int J Obes Relat Metab Disord. 2002;26 Suppl. 4: S29-33
49. Finer N. Pharmacotherapy of obesity. Best Practice & Research Clinical Endocrinology and Metabolism 2002; 16(4):717-742.
50. Morris PJ, Pakianathan CI, Van Blerk CJ, Finer N. Moderate exercise and fibrinolytic potential in obese sedentary men with metabolic syndrome. Obesity Research 2003; 11: 1333-1338
51. Burcombe RJ, Makris A, Pittam M, Finer N. Breast cancer after bilateral subcutaneous mastectomy in a female-to-male trans-sexual. The Breast. 2003; 12: 290-93.
52. van Baak MA, van Mil E, Astrup AV, Finer N, Van Gaal LF, Hilsted F, Kopelman PG, Rössner S, James WP, Saris WHM for the STORM Study Group. Leisure time activity is an important determinant of long-term weight maintenance after weight loss in the Sibutramine Trial on Obesity Reduction and Maintenance (STORM trial). American Journal of Clinical Nutrition 2003; 78: 209-14.
53. Counterweight Project team. A new evidence-based model for weight management in primary care: The Counterweight Programme. Journal of Hospital Nutrition and Dietetics 2004; 17: 191-208
54. Counterweight Project team. Current approaches to obesity management in UK primary care: The Counterweight Programme. Journal of Hospital Nutrition and Dietetics 2004; 17: 183-190
55. Packianathan I, Sheikh M, Boniface D, Finer N. Predictors of programme adherence and weight loss in women in an obesity programme using meal replacements. Diabetes Obesity and Metabolism 2005; 7(4): 439-447 + 2005; 7(4): 461.
56. J Wilding, L Van Gaal, A Rissanen, F Vercruysse and M Fitchet for the OBES-002 Study Group. A randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects. International Journal of Obesity (2004) 28, 1399–1410
57. Obesity Management Taskforce of EASO (Chair Hainer V, Vice-chairs Finer N, Tsigos C). Management of Obesity in Adults: Project for European Primary Care. International Journal of Obesity (2004) 28, S226–S231.
58. IC Packianathan, NJ Fuller, DB Peterson, A Wright, WA Coward, N Finer. Use of a reference four-component model to evaluate the ability of alternative methods and prediction techniques to estimate body composition in Type 2 diabetes and its changes following insulin treatment. Int J Body Comp Research 2005;2 (4): 141-148.
59. P. M. J. Zelissen, K. Stenlof, M. E. J. Lean, J. Fogteloo, E. T. P. Keulen, J. Wilding, N. Finer, S. Rössner, E. Lawrence, C. Fletcher, M. McCamish, on behalf of the author group. Effect of three treatment schedules of recombinant methionyl human leptin on body weight in obese adults: a randomized, placebo-controlled trial. Diabetes, Obesity and Metabolism 2005; 7:755-761.
60. IC Packianathan, NJ Fuller, DB Peterson, A Wright, WA Coward, N Finer. Use of a reference four-component model to define the effects of insulin treatment on body composition in Type 2 diabetes: the 'DARWIN STUDY'. Diabetologia. 2005;48(2):222-9.
61. Sauerland S, Angrisani L, Belachew M, Chevallier JM, Favretti F, Finer N, et al. Obesity surgery: Evidence-based guidelines of the European Association for Endoscopic Surgery (EAES). Surgical Endoscopy and Other Interventional Techniques 2005; 19(2):200-221.
62. Finer N and Pagotto U. The endocannabinoid system: a new therapeutic target for cardiovascular risk management. 2005. British Journal of Cardiovascular and Diabetes 2005; 5:121-4.
63. The Counterweight Project Team: McQuigg M, Brown J, Broom J, Laws RA, Reckless JPD, Noble PA, Kumar S, McCombie EL, Lean MEJ, Lyons GF, Frost GS, Quinn MF, Barth JH, Haynes SM, Finer N Ross HM, Hole DJ. Empowering primary care to tackle the obesity epidemic: The Counterweight Programme. European Journal of Clinical Nutrition. 2005; 59, Suppl. 1, S903-S101
64. Broom J, Brown J *Laws RA, Reckless JPD, Noble PA, Kumar S, McCombie EL, Lean MEJ, Lyons GF, Frost GS, Quinn MF, Barth JH, Haynes SM, Finer N Ross HM, Hole DJ. Obesity impacts on general practice appointments. Obesity Research 2005;13 (8):1442-49.
65. The Counterweight Project Group: McQuigg M, Brown J, Broom J, Laws RA, Reckless JPD, Noble PA, Kumar S, McCombie EL, Lean MEJ, Lyons GF, Frost GS, Quinn MF, Barth JH, Haynes SM, Finer N Ross HM, Hole DJ. The impact of obesity on drug prescribing in primary care. British Journal of General Practice 2005; 55:743-49.
66. N. Finer. Does pharmacologically induced weight loss improve cardiovascular outcome? Impact of anti-obesity agents on cardiovascular risk factors. Eur Heart J Suppl. (November 2005) 7 (Suppl. L): L32-L38. doi: 10.1093/eurheartj/sui084
67. Finer N. Aspartame and its effects on health: approach seems simplistic. Electronic responses to editorial. BMJ. 2005 Feb 5; 330(7486):310 (Letter)
68. Finer N. Rationing joint replacements. BMJ 2005; 331:1472 (Letter)
69. Wilding J and Finer N. Interheart Study. Lancet 2006; 367:1053 (Letter)
70. N. Finer, D. H. Ryan, C. L. Renz and A. C. Hewkin. Prediction of response to sibutramine therapy in obese non-diabetic and diabetic patients. Diabetes, Obesity and Metabolism 2006;8(2):206-13.
71. Tuthill A, Slawik H, O’Rahilly, S, Finer N. Psychiatric co-morbidities in patients attending specialist obesity services in the UK. Quarterly Journal of Medicine 2006: 99:317-325
72. Miguel López, Christopher J. Lelliott, Sulay Tovar, Wendy Kimber, Rosalía Gallego, Sam Virtue, Margaret Blount, Maria J. Vázquez, Nick Finer, Trevor J. Powles, Stephen O’Rahilly, Asish K. Saha, Carlos Diéguez, and Antonio J. Vidal-Puig. Tamoxifen-Induced Anorexia Is Associated with Fatty Acid Synthase Inhibition in the Ventromedial Nucleus of the Hypothalamus and Accumulation of Malonyl-CoA. Diabetes 55:1327-1336, 2006
73. Caterson I and Finer N. Emerging pharmacotherapy for treating obesity and associated cardiometabolic risk. Asia Pac J Clin Nutr 2006;15 (Suppl): 55-62
74. Scheen A, Finer N et al. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet 2006; 368:1660-1672
75. Lean M and Finer N. ABC Obesity: Management Part II: Drugs. Br Med J 2006; 333:794-7
76. H Toplak, A Hamann, R Moore, E Masson, M Gorska, F Vercruysse, X Sun and M Fitchet for the OBDM-002 Study Group. Efficacy and safety of topiramate in combination with metformin in the treatment of obese subjects with type 2 diabetes: a randomized, double-blind, placebo-controlled study. International Journal of Obesity 2006; 31, 138–146.
77. Astrup A, Greenway FL, Ling W, Pedicone L, Lachowicz J, Strader CD, Kwan R for the Ecopipam Obesity Study Group. Randomized Controlled Trials of the D1/D5 Antagonist Ecopipam for Weight Loss in Obese Subjects. Obesity. 2007; 15:1717–1731
78. M Fried, V Hainer, A Basdevant, H Buchwald, M Deitel, N Finer et al. Inter-disciplinary European guidelines on surgery of severe obesity. Int J Obesity 2007; 31:569-77
79. Finer N. Drug treatments for obesity. Lancet 2007; 369:1163 (letter)
80. Svensson J, Finer N, Bouloux P, Bevan J et al. Growth hormone (GH) replacement therapy in GH deficient adults: predictors of one-year metabolic and clinical response. Growth Hormone IGF Research 2007; 17:67-76.
81. M Fried, V Hainer, A Basdevant, H Buchwald, M Deitel, N Finer et al. Inter-disciplinary European guidelines on surgery of severe (morbid) obesity. Obesity Surgery 2007; 17:260-70
82. Torp-Pedersen C, Caterson I, Coutinho W, Finer N, et al. Cardiovascular Responses to Weight Management and Sibutramine in High-Risk Subjects – An Analysis from the SCOUT Trial. European Heart Journal 2007; 28:2915-23
83. Wittert GA, Caterson I, Finer N. The Clinical Effectiveness of Weight Loss Drugs. Obesity Research in Clinical Practice 2007 1(1):1-5.
84. Levy P, Fried M, Santini F, Finer N. The comparative effects of bariatric surgery on body weight and type 2 diabetes: a review of the literature. Obesity Surgery 2007,17(9):1248-56.
85. K. Elfhag, N. Finer and S. Rössner. Who will lose weight on Sibutramine and Orlistat? Psychological Correlates for Treatment Success. Diabetes, Obesity and Metabolism 2008; 10(6):498-505
86. Napolitano A, Miller SR, Murgatroyd PR, Coward WA, Wright A, Finer N, et al. Validation of a quantitative magnetic resonance method for measuring human body composition. Obesity 2008; 16:191-8
87. McQuigg M, Brown JE, Broom J, Laws RA, Reckless JPD, Noble PA, Kumar A, McCombie EL, Lean MEJ, Lyons FG, Frost GS, Quinn MF, Barth JH, Haynes SM, Finer N et al. The Counterweight programme: Prevalence of CVD risk factors by body mass index and the impact of 10% weight change. Obesity Research & Clinical Practice (2008) 2, 15—27
88. Browning LM, Krebs JD, Siervo M, Hall RM, Finer N, Allison ME, Jebb SA. Inflammation is associated with liver function markers, independent of other metabolic risk factors in overweight women. Br J Diabetes Vasc Dis 2008; 8:73-6.
89. Fried M, Hainer V, Basdevant A, Buchwald H, Deitel M, Finer N, Greve JW, Horber F, Mathus-Vliegen E, Scopinaro N, Steffen R, Tsigos C, Weiner R, Widhal. Interdisciplinary European Guidelines on Surgery of Severe Obesity. Obes Facts. 2008;1(1):52-59
90. Fried M, Hainer V, Basdevant A, Buchwald H, Deitel M, Finer N, Greve JW, Horber F, Mathus-Vliegen E, Scopinaro N, Steffen R, Tsigos C, Weiner R, Widhal. Interdisciplinary European Guidelines on Surgery of Severe Obesity. Rozhl. Chir. 2008;87(9):466-76.
91. Goodman AO, Murgatroyd PR, Medina-Gomez G, Wood NI, Finer N et al. The metabolic profile of early Huntington's disease- a combined human and transgenic mouse study. Exp Neurol. 2008;210(2):691-8.
92. Wolf AM, Finer N et al. PROCEED: Prospective Obesity Cohort of Economic Evaluation and Determinants: Baseline Health and Health Care. Utilization of the US Sample. Diabetes, Obesity Metabolism 2008 Dec;10(12):1248-60.
93. Maggioni AP, Caterson I, Coutinho W, Finer N et al. Tolerability of Sibutramine During a 6-Week Treatment Period in High-Risk Patients with Cardiovascular Disease and/or Diabetes - A Preliminary Analysis of the Sibutramine Cardiovascular Outcomes (SCOUT) Trial. Journal of Cardiovascular Pharmacology 2008; 52:393–402
94. Tsigos C, Hainer V, Basdevant A, Finer N et al. Management of Obesity in Adults: European clinical practice guidelines. Obesity Facts 2008;1(2):106-16
95. Interdisciplinary European guidelines on surgery for severe obesity. Fried M, Hainer V, Basdevant A, Buchwald H, Dietel M, Finer N, Greve JW, Horber F, Mathus-Vliegen E, Scopinaro N, Steffen R, Tsigos C, Weiner R, Widhalm K. Rozhl Chir. 2008 Sep;87(9):468-76
96. Fried M, Hainer V, Basdevant A, Buchwald H, Dietel M, Finer N, Greve JW, Horber F, Mathus-Vliegen E, Scopinaro N, Steffen R, Tsigos C, Weiner R, Widhalm K Inter-disciplinary European guidelines on surgery of severe obesity. Vnitr Lek. 2008 Apr;54(4):421-9.
97. Counterweight Project Team, M. McQuigg, J.E. Brown, J. Broom, R.A. Laws, J.P.D. Reckless, P.A. Noble, S. Kumar, E.L. McCombie, M.E.J. Lean, F.G. Lyons, G.S. Frost, M.F. Quinn, J.H. Barth, S.M. Haynes, N. Finer, D.W. Haslam, H.M. Ross, D.J. Hole, S. Radziwonik. The Counterweight programme: Prevalence of CVD risk factors by body mass index and the impact of 10% weight change. Obesity Research & Clinical Practice, Volume 2, Issue 1, March 2008, Pages 15-27
98. Counterweight Project Team. Evaluation of the Counterweight Programme for obesity management in primary care: a starting point for continuous improvement. Br J Gen Pract. 2008 Aug;58(553), 548-554
99. Counterweight Project Team. Influence of body mass index on prescribing costs and potential cost savings of a weight management programme in primary care. Journal of Health Services Research & Policy Vol 13 No 3, 2008: 158–166
100. Counterweight Project Team. Engaging patients, clinicians and health funders in weight management: The Counterweight Program. Journal of Family Practice Family Practice. 2008 Dec;25(S1), I79-I86
101. Sharma AM, Caterson ID, Coutinho W, Finer N, Van Gaal L, Maggioni AP, Torp-Pedersen C, Bacher CP, Shepherd GM and James WPT, on the behalf of the SCOUT Investigators. Blood Pressure Changes Associated with Sibutramine and Weight Management – An Analysis from the 6-Week Lead-in Period of the Sibutramine Cardiovascular Outcomes (SCOUT) Trial. Diabetes Obesity Metabolism. 2009, 11:239-250.
102. Sharma V, Braithewaite A, Harger S, Finer N. Obesity remains under diagnosed in English hospital in-patients. Obesity Research and Clinical Practice. 2009 March: 3(1): 17-20.
103. Brown LA, Van Blerk C, Whiting P, Finer N; McEneny J, Ashton T. Oxidant stress in healthy normal-weight, overweight and obese individuals. Obesity (Silver Spring). 2009 Mar;17(3):460-6
104. Ian Caterson, Walmir Coutinho, Nick Finer, et al. Early Response to Sibutramine in Patients Who Did Not Meet Current Label Criteria: Preliminary Analysis of Lead-In Period of the SCOUT Trial. Obesity (Silver Spring, Md.) 2010;18(5):987-94
105. Andersson C, Weeke P, Fosbøl EL, Brendorp B, Køber L, Coutinho W, Sharma AM, Van Gaal L, Finer N et al. Acute effect of weight loss on levels of total bilirubin in obese, cardiovascular high-risk patients: an analysis from the lead-in period of the Sibutramine Cardiovascular Outcome trial. Metabolism. 2009 Aug;58(8):1109-15.
106. Astrup A et al on behalf of the NN8022-1807 Study Group. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet 2009 Nov 7;374(9701):1606-16
107. Andersson C, Weeke P, Brendorp B, Køber L, Fosbøl EL, Sharma AM, Finer N, Caterson ID, Rode RA, James PT, Torp-Pedersen C Differential changes in serum uric acid concentrations in sibutramine promoted weight loss in diabetes: results from four weeks of the lead-in period of the SCOUT trial. Nutr Metab (Lond). 2009 Oct 14; 6: 42
108. Luc Van Gaal, Ian D Caterson, Walmir Coutinho, Nick Finer, et al. Weight and Blood Pressure Response to Weight Management and Sibutramine in Diabetic and non-Diabetic High-Risk Patients: An Analysis from the 6-Week Lead-in Period of the Sibutramine Cardiovascular Outcomes (SCOUT) Trial. Diabetes, Obesity Metabolism. 2010 Jan;12(1):26-34
109. Fried, M., Hainer, V., Basdevantc, A., Buchwald, H., Deitel, M., Finer, N., Scopinaro, N. (2009). Interdisciplinary European Guidelines on surgery of severe obesity. Postepy Nauk Medycznych, 22 (7), 554-562.
110. Khin Swe Myint, Antonella Napolitano, Sam Miller, Peter R. Murgatroyd, Maysoon Elkhawad, Derek J.R. Nunez, Nick Finer. The use of a novel quantitative magnetic resonance method for the longitudinal evaluation of changes in human body composition following two different weight loss regimens. Obesity 2010 Feb;18(2):391-6
111. Weeke P, Andersson C, Fosbol EL, Brendorp B, Kober L, Sharma AM, Finer N et al. The weight lowering effect of Sibutramine and its impact on serum lipids in cardiovascular high-risk patients with and without type 2 diabetes – an analysis from the SCOUT lead-in period. BMC Endocr Disord. 2010 Feb 26; 10:3
112. Finer N; On behalf of the Executive Steering Committee of the Sibutramine Cardiovascular Outcome Trial (SCOUT): Ian Caterson, Walmir Coutinho, Luc Van Gaal, Aldo Maggioni, Christian Torp-Pedersen, Arya Sharma, and Philip James Editorial is judgment in advance of the facts. BMJ. 2010 Mar 10;340:c1346
113. The Counterweight Project Team. Economic evaluation of the long-term effects of the counterweight programme to manage obesity. Int J Clin Pract. 2010 May;64(6):775-83
114. Pendergast K, Wolf A, Sherrill B, Zhou X, Aronne LJ, Caterson I, Finer N, Hauner H, Hill J, Van Gaal L, Coste F, Despres JP. Impact of Waist Circumference Difference on Health-Care Cost among Overweight and Obese Subjects: The PROCEED Cohort. Value Health. 2010 Jun-Jul;13(4):402-10
115. Lean ME, Reckless JP, Finer N, McCombie L Counterweight - counter-cost, counter-loss. Int J Clin Pract. 2010 May;64(6):828-9
116. Finer N; Executive Steering Committee of the Sibutramine Cardiovascular Outcome Trial Withdrawal of sibutramine. Editorial is judgment in advance of the facts. BMJ. 2010 Mar 10;34
117. Napolitano A, Murgatroyd PR, Finer N, Hussey EK, Dobbins R, O'Rahilly S, Nunez DJR. Assessment of Acute and Chronic Pharmacological Effects on Energy Expenditure and Macronutrient Oxidation in Humans: Responses to Ephedrine. Journal of Obesity, vol. 2011, Article ID 210484, 8 pages, 2011. doi:10.1155/2011/210484
118. James WPT, Caterson I, Coutinho W, Finer N et al. Effect of Sibutramine on Cardiovascular Outcomes in Overweight and Obese. New Engl J Med. 2010 363: 1905-17.
119. Falaschetti E, Aroon D. Hingorani AD, Jones A, Charakida M, Finer N, Whincup P, Lawlor DA, Smith GD, Sattar N, Deanfield JE. Adiposity and cardiovascular risk factors in a large contemporary population of pre-pubertal children Eur Heart J. 2010 Dec;31(24):3063-72. doi: 10.1093/eurheartj/ehq355. Epub 2010 Oct 23
120. Aronne LJ, Finer N et al. Efficacy and Safety of CP-945,598, a Selective Cannabinoid CB1 Receptor Antagonist, on Weight Loss and Maintenance. Obesity (Silver Spring). 2011 Jul;19(7):1404-14.
121. Savory LA, Kerr CJ, Whiting P, Finer N, McEneny J, Ashton T. Selenium Supplementation & Exercise: Effect on Oxidant Stress in Overweight Adults. Obesity (Silver Spring). 2012 Apr;20(4):794-801.
122. Astrup A, Al Hakim M, Carraro R, Finer N et al. Sustained Weight Loss with Diet and Liraglutide for Obesity: A 52-week Dose-ranging Randomized. Int J Obes (Lond). 2012 Jun;36(6):843-54. doi: 10.1038/ijo.2011.158. Epub 2011 Aug 16. Erratum in: Int J Obes (Lond). 2012 Jun;36(6):890
123. Counterweight Project Team. The implementation of the Counterweight Programme in Scotland, UK. Fam Pract. 2012 Apr;29 Suppl. 1: i139-i144.
124. Tsigos C, Hainer V, Basdevant A, Finer N et al. Criteria for EASO-Collaborating Centres for Obesity Management. Obes Facts 2011;4: 329–333
125. Caterson I, Finer N et al. Maintained Intentional Weight Loss Reduces Cardiovascular Outcomes: Results from the Sibutramine Cardiovascular Outcomes (SCOUT) Trial. Diabetes Obes Metab. 2012 Jun;14(6):523-30.
126. Charakida M and Finer N. Drug Treatment of Obesity In Cardiovascular Disease. Am J Cardiovasc Drugs. 2012 Apr 1;12(2):93-104.
127. Counterweight Project Team. The implementation of the Counterweight Programme in Scotland. Family Practice 2011;29 Suppl. 1; i139-i144.
128. Myint KS, Greenfield JR, Henning E, Farooqi S, Holst J, Finer N. Prolonged Successful therapy for Hyperinsulinaemic Hypoglycaemia after Gastric Bypass: The Pathophysiological Role Of GLP-1 and its Response to A Somatostatin Analogue. Eur J Endocrinol. 2012 May;166(5):951-5. Epub 2012 Mar 9.
129. Alexander Jones, Marietta Charakida, Emanuela Falaschetti, Aroon D. Hingorani, Nicholas Finer, Stefano Masi, Ann E. Donald, Debbie A. Lawlor, George Davey Smith, John E. Deanfield, Adipose and Height Growth Through Childhood And Blood Pressure Status In A Large Prospective Cohort Study. Hypertension. 2012 May;59(5):919-25. Epub 2012 Apr 9.
130. Jens Jordan, Volkan Yumuk, Markus Schlaich, Peter M. Nisson, Barbara Zahorska-Markiewicz, Guido Grassi, Roland E. Schmieder, Arnaud Basdevant, Stefan Engeli, Nick Finer. Joint Statement of The European Association for The Study Of Obesity And The European Society Of Hypertension: Obesity And Difficult To Treat Arterial Hypertension. Journal of Hypertension 2012 Jun;30(6):1047-1055
131. L. McCombie, M. E. J. Lean, D. Haslam on behalf of The Counterweight Project Team. Effective UK weight management services for adults. Clinical Obesity 2012. doi: 10.1111/j.1758-8111.2012.00049.x
132. Mathus-Vliegen EM, Basdevant A, Finer N et al. Prevalence, pathophysiology, health consequences and treatment options of obesity in the elderly: a guideline. Obes Facts. 2012;5(3):460-83. Epub 2012 Jun 30.
133. Andersson C, van Gaal L, Caterson ID, Weeke P, James WP, Couthino W, Finer N et al. Relationship between HbA1c levels and risk of cardiovascular adverse outcomes and all-cause mortality in overweight and obese cardiovascular high-risk women and men with type 2 diabetes. Diabetologia. 2012 Sep;55(9):2348-55. Epub 2012 May 26.
134. Charakida M, Jones A, Falaschetti E, Khan T, Finer N et al. Childhood Obesity and Vascular Phenotypes: A Population Study. Journal of American Cardiology 2012 2012 Dec 25;60(25):2643-50
135. Counterweight Project Team. Working with Obesity. Counterweight: An evidence-based programme for weight management in the workplace. Clinical Obesity 2012.
136. Helle Skak-Nielsen Charlotte Andersson Christian Torp-Pedersen, Nicholas Finer et al. Uric Acid as A Risk Factor For Cardiovascular Disease And Mortality. PLoS One. 2013;8(3): e59121. doi: 10.1371/journal.pone.0059121. Epub 2013 Mar 22
137. Astrup A, Rössner S, Finer N, Van Gaal L. Obesity in Europe - does anybody care? Expert Opin Pharmacother. 2013 Jun;14(8):971-3
138. Wass J, Finer N. Action on obesity: comprehensive care for all. Clin Med. 2013 Feb;13(1):4-5.
139. Lean M, Brosnahan N, McLoone P, McCombie L, Higgs AB, Ross H, Mackenzie M, Grieve E, Finer N, Reckless J, Haslam D, Sloan B, Morrison D. Feasibility and indicative results from a 12-month low-energy liquid diet treatment and maintenance programme for severe obesity. Br J Gen Pract. 2013 Feb;63(607): e115-24. doi: 10.3399/bjgp13X663073.
140. Winther SA, Finer N, Sharma AM, Torp-Pedersen C, Andersson C. Association of anemia with the risk of cardiovascular adverse events in overweight/obese patients. Int J Obes (Lond). 2013 Jun 18.doi: 10.1038/ijo.2013.111. [Epub ahead of print]
141. Manning SB, Pucci A, Batterham RL, Finer N. Latent autoimmune diabetes in adults presenting as diabetes "recurrence" after bariatric surgery: a case report. Diabetes Care. 2013 Aug;36(8)
142. Charakida M, Tousoulis D, Finer N. Drug treatment of obesity in the cardiovascular patient. Curr Opin Cardiol. 2013 Sep;28(5):584-91
143. Jackson SE, Wardle J, Johnson F, Finer N, Beeken RJ. The impact of a health professional recommendation on weight loss attempts in overweight and obese British adults: a cross-sectional analysis. BMJ Open. 2013 Nov 4;3(11):e003693. doi: 10.1136/bmjopen-2013-003693.
144. Ghotbi AA, Køber L, Finer N, James WP, Sharma AM, Caterson I, Coutinho W, Van Gaal LF, Torp-Pedersen C, Andersson C. Association of Hypoglycemic Treatment Regimens with Cardiovascular Outcomes in Overweight and Obese Subjects With Type 2 Diabetes: A substudy of the SCOUT trial. Diabetes Care. 2013 Nov;36(11):3746-53. doi: 10.2337/dc13-0027. Epub 2013 Oct 2.
145. Lean MEJ, Carraro R, Finer N et al. on behalf of the NN8022-1807 Investigators. Influence of nausea and vomiting on weight-loss, quality of life and continuation of liraglutide treatment in obese non-diabetic adults. Int J Obes (Lond). 2014; 38(5):685-97. doi: 10.1038/ijo.2013.149.
146. Finer N. Clinical pictures. Clinical Obesity 2014; 4(2):125-6.
147. Yousseif A, Emmanuel J, Karra E, Millet Q, Elkalaawy M, Jenkinson AD, Hashemi M, Adamo M, Finer N, Fiennes AG, Withers DJ, Batterham RL. Differential Effects of Laparoscopic Sleeve Gastrectomy and Laparoscopic Gastric Bypass on Appetite, Circulating Acyl-ghrelin, Peptide YY3-36 and Active GLP-1 Levels in Non-Diabetic Humans. Obesity Surgery. 2014; 24:241–252
148. Seimon RV, Espinoza D, Ivers L, Gebski V, Finer N et al. Changes in Body Weight and Blood Pressure: Paradoxical Outcome Events in Overweight and Obese Subjects with Cardiovascular Disease. Int J Obes (Lond). 2014 Sep;38(9):1165-71. doi: 10.1038/ijo.2014.2.
149. Jordan J, Astrup A, Engeli S, Narkiewicz, Day WW, Finer N. Cardiovascular Effects of Phentermine and Topiramate - a New Drug Combination for the Treatment of Obesity. Journal of Hypertension 2014; 32960;1178-88.mm
149. Jørgensen ME, Torp-Pedersen C, Finer N, Caterson I, James WP, Legler UF, Andersson C. Association between serum bilirubin and cardiovascular disease in an overweight high risk population from the SCOUT trial. Nutr Metab Cardiovasc Dis. 2014; 24(6):656-62.
150. Charakida M, Khan T, Johnson W, Finer N, Woodside J, Whincup PH, Sattar N, Kuh D, Hardy R, Deanfield J. Lifelong patterns of BMI and cardiovascular phenotype in individuals aged 60-64 years in the 1946 British birth cohort study: an epidemiological study. Lancet Diabetes Endocrinol. 2014; 2(8):648-54.
151. Manning S, Pucci A, Finer N. Pharmacotherapy for obesity: novel agents and paradigms. Ther Adv Chronic Dis. 2014 May;5(3):135-148. Review. PMID: 24790728
152. Smith SR, O'Neil PM, Astrup A, Finer N, Sanchez-Kam M, Fraher K, Fain R, Shanahan WR. Early weight loss while on lorcaserin, diet, and exercise as a predictor of week 52 weight-loss outcomes. Obesity 2014;22(10):2137-46. doi: 10.1002/oby.20841.
153. Finer N. Sarcopenic obesity: under recognised and over treated? Clinical Medicine 2014; 14(4):454. Doi: 10.786/clinmedicine.14-4-454.
154. Manning S, Carter NC, Pucci A, Jones A, Elkalawy M, Cheung W-H, Mohammadi B, Finer N et al. Age- and sex-specific effects on weight loss outcomes in a comparison of sleeve gastrectomy and Roux-en-Y gastric bypass: a retrospective cohort study. BMC Obesity 2014, 1:12. doi:10.1186/2052-9538-1-12.
155. Geiker NRW, Myint KS, Heck P, Dhatariya K, Larsen SH, Andersen MR, Stender M, Torp-Pedersen C, Finer N, Astrup A. Intentional weight loss improved physical and cardiac performance in obese patients with ischaemic heart disease: A two centre intervention trial. Jacobs Journal of Food and Nutrition. 2014;1(1):003
156. Manning S, Finer N, Elkalaawy M, Hashemi M, Jenkinson AD, Adamo A, O’Brien P, Batterham RL, Richens Y. Timing of pregnancy in obese women after bariatric surgery. Pregnancy Hypertension: An International Journal of Women's Cardiovascular Health. 2014; 4(3):235.
157. Manning S, Pucci A, Carter NC, Elkalaawy M, Querci G, Magno S, Tamberi A, Finer N, Fiennes AG, Hashemi M, Jenkinson AD, Anselmino M, Santini F, Adamo M, Batterham RL. Early postoperative weight loss predicts maximal weight loss after sleeve gastrectomy and Roux-en-Y gastric bypass. Surgical Endoscopy 2015; 29 (6), pp. 1484-1491 doi 10.1007/s00464-014-3829-7
158. Finer N. Comment on Balkau et al. Factors associated with weight gain in people with type 2 diabetes starting on insulin. Diabetes Care 2014; 37:2108-2113.
159. Jordan J, Nilsson PM, Kotsis V, Olsen MH, Grassi G, Yumuk V, Hauner H, Zahorska-Markiewicz B, Toplak H, Engeli S, Finer N. Joint scientific statement of the European Association for the Study of Obesity and the European Society of Hypertension: obesity and early vascular ageing. J Hypertens. 2015 Mar;33(3):425-34
160. Seimon RV, Espinoza D, Finer N, James WP, Legler UF, Coutinho W, Sharma AM, Van Gaal L, Maggioni AP, Sweeting A, Torp-Pedersen C, Gebski V, Caterson ID. Changes in body weight and pulse: outcome events in overweight and obese subjects with cardiovascular disease in the SCOUT trial. Int J Obes (Lond). 2014 Dec 18. doi: 10.1038/ijo.2014.211.
161. Finer N. Clinical obesity comes of age. Clin Obes. 2015 Feb;5(1):1. doi: 10.1111/cob.12087. PMID: 25611583
162. Jordan J, Nilsson PM, Kotsis V, Olsen MH, Grassi G, Yumuk V, Hauner H, Zahorska-Markiewicz B, Toplak H, Engeli S, Finer N. Joint scientific statement of the European Association for the Study of Obesity and the European Society of Hypertension: Obesity and early vascular ageing. J Hypertens. 2015 Mar;33(3):425-34
163. Finer N. Predicting therapeutic weight loss. Am J Clin Nutr. 2015 Mar;101(3):419-20. doi: 10.3945/ajcn.114.106195. Epub 2015 Jan 28. PMID: 2573362
164. Pucci A, Finer N. New medications for treatment of obesity: metabolic and cardiovascular effects. Can J Cardiol. 2015 Feb;31(2):142-52. doi: 10.1016/j.cjca.2014.11.010. Epub 2014 Nov 14. PMID: 2566154
165. Friedrich Jassill, Sean Manning, Neville Lewis, Siri Steinmo, Helen Kingett, Fiona Lough, Andrea Pucci, Wui-Hang Cheung, Nick Finer, Judith Walker, Jacqueline Doyle and R. Batterham. Feasibility and Impact of a Combined Supervised Exercise and Nutritional-Behavioral Intervention Following Bariatric Surgery: A Pilot Study. J Obes. 2015;2015:693829. doi: 10.1155/2015/693829. Epub 2015 Jun 23.
166. Katherine E. Manning, Catherine J. McAllister, Howard A. Ring, Nicholas Finer, Claire L. Kelly, Karl P. Sylvester, Paul C. Fletcher, Nicholas W. Morrell, Matthew R. Garnett, Mark R.A. Manford, and Anthony J. Holland. Novel insights into maladaptive behaviours in Prader-Willi syndrome: serendipitous findings from an open trial of vagus nerve stimulation. J Intellectual Disability Research 2016; 60 (2), pp. 149-155
167. Andrea Pucci, Wui Hang Cheung, Jenny Jones, Sean Manning, Helen Kingett, Marco Adamo, Mohamed Elkalaawy, Andrew Jenkinson, Nicholas Finer, Jacqueline Doyle, Majid Hashemi and Rachel L Batterham. A case of severe anorexia, excessive weight loss and high peptide YY levels after sleeve gastrectomy. Endocrinology, Diabetes & Metabolism Case Reports, 6 2015, EDM150020, 10.1530/EDM-15-0020.
168. Leiter LA, Astrup A, Andrews RC, Cuevas A, Horn DB, Kunešová M, Wittert G, Finer N. Identification of educational needs in the management of overweight and obesity: results of an international survey of attitudes and practice. Clin Obes. 2015 Aug 4. doi: 10.1111/cob.12109.
169. Richard Welbourn, John Dixon, Julian H. Barth, Nicholas Finer, Carly A. Hughes, Carel W. le Roux, John Wass, on behalf of the Guidance Development Group NICE-Accredited Commissioning Guidance for Weight Assessment and Management Clinics: a Model for a Specialist Multidisciplinary Team Approach for People with Severe Obesity. Obesity Surgery. 2016. online DOI 10.1007/s11695-015-2041-8
170. Zomer E, Gurusamy K, Leach R, Trimmer C, Lobstein T, Morris S, James WP, Finer N. Interventions that cause weight loss and the impact on cardiovascular risk factors: a systematic review and meta-analysis. Obes Rev. 2016 Jun 21. doi: 10.1111/obr.12433.
171 Jordan J, Toplak H, Grassi G, Yumuk V, Kotsis V, Engeli S, Cuspidi C, Nilsson PM, Finer N, Doehner W. Joint statement of the European Association for the Study of Obesity and the European Society of Hypertension: obesity and heart failure. J Hypertens. 2016 Sep;34(9):1678-88.
172 Makaronidis JM, Neilson S, Cheung WH, Tymoszuk U, Pucci A, Finer N, Doyle J, Hashemi M, Elkalaawy M, Adamo M, Jenkinson A, Batterham RL. Reported appetite, taste and smell changes following Roux-en-Y gastric bypass and sleeve gastrectomy: Effect of gender, type 2 diabetes and relationship to post-operative weight loss. Appetite. 2016 Jul 22; 107:93-105. doi: 10.1016/j.appet.2016.07.029.
173 Uerlich MF, Yumuk V, Finer N, Basdevant A, Visscher TL. Obesity Management in Europe: Current Status and Objectives for the Future. Obes Facts. 2016;9(4):273-83. doi: 10.1159/000445192. Epub 2016 Aug 20. PMID: 27553443
174 Zomer E, Leach R, Trimmer C, Lobstein T, Morris S, James WP, Finer N. Effectiveness and cost-effectiveness of interventions that cause weight loss and reduce the risk of cardiovascular disease. Diabetes Obes Metab. 2016 Sep 20. doi: 10.1111/dom.12792. [Epub ahead of print] PMID: 27649286
175 Kamil S, Finer N, James WP, Caterson ID, Andersson C, Torp-Pedersen C. Influence of sibutramine in addition to diet and exercise on the relationship between weight loss and blood glucose changes. Eur Heart J Cardiovasc Pharmacother. 2016 Sep 27. pii: pvw029.
176 MacLaughlin H, Macdougall IC, Finer N, Johansson L, Frankel AH. The London Renal Obesity Network protocol for bariatric surgery in patients with CKD. British Journal of Renal Medicine 2016, 21(2), 32-34.
177 Coulman KD, Hopkins J, Brookes ST, Chalmers K, Main B, Owen-Smith A, Andrews RC, Byrne J, Donovan JL, Mazza G, Reeves BC, Rogers CA, Thompson JL, Welbourn R, Wordsworth S, Blazeby JM, BARIACT Working Group. A Core Outcome Set for the Benefits and Adverse Events of Bariatric and Metabolic Surgery: The BARIACT Project. PLoS Med 13(11): e1002187. doi:10.1371/journal.pmed.1002187
178 Aldo P Maggioni, MD, Ian D Caterson, MD, Renato Urso, MS, Walmir Coutinho, MD,
Nick Finer, MD, Luc Van Gaal, MD, Udo F Legler, MD, Arya M Sharma, MD, Radhika V
Seimon, PhD, Arianne Sweeting, MD, Christian Torp-Pedersen, MD, W Philip T James,
MD. Relation between weight loss and causes of death in patients with cardiovascular disease: finding from the SCOUT trial. Journal of Cardiovascular Medicine 18(3):144-151, March 2017
179 Mead E, Atkinson G, Richter B, Metzendorf MI, Baur L, Finer N, Corpeleijn E, O'Malley C, Ells LJ. Drug interventions for the treatment of obesity in children and adolescents. Cochrane Database Syst Rev. 2016 Nov 29
180 Lenoir-Wijnkoop I, Mahon J, Claxton L, Wooding A, Prentice A, Finer N. An economic model for the use of yoghurt in type 2 diabetes risk reduction in the UK. BMC Nutrition (2016) 2:77. DOI 10.1186/s40795-016-0115-1
181 Jamieson A, Finer N. Can we reconcile 'the obesity paradox' with recent cardiovascular outcome trials in diabetes? Clin Obes. 2017 Oct;7(5):255-259. doi: 10.1111/cob.12217
182 Beeken RJ, Croker H, Heinrich M, Obichere A, Finer N, Murphy N et al. The impact of diet-induced weight loss on biomarkers for colorectal cancer. An exploratory study (INTERCEPT). Obesity (Silver Spring). 2017 Nov;25 Suppl 2:S95-S101. doi: 10.1002/oby.21984.
183 Welbourn R, Hopkins J, Dixon JB, Finer N, Hughes C, Viner R, Wass J; Guidance Development Group. Commissioning guidance for weight assessment and management in adults and children with severe complex obesity. Obes Rev. 2018; 19:14-27.
184 Pucci A, Tymoszuk U, Cheung WH, Makaronidis JM, Scholes S, Tharakan G, Elkalaawy M, Guimares M, Nora M, Hashemi M, Jenkinson A, Adamo M, Monteiro MP, Finer N, Batterham ML. Type 2 diabetes remission 2 years post Roux-en-Y gastric bypass and sleeve gastrectomy: the role of the weight loss and comparison of DiaRem and DiaBetter scores. Diabetic Med 2018; 35: 360-67.
185 Lessan N, Saadane I, Alkaf B, Hambly C, Buckley AJ, Finer N, Speakman JR, Barakat MT. The effects of Ramadan fasting on activity and energy expenditure. Am J Clin Nutr 2018; 107:54-61.
186 Kotsis V, Jordan J, Micic D, Finer N, Leitner DR, Toplak H, Tokgozoglu L, Athyros V, Elisaf M, Filippatos TD, Redon J, Redon P, Antza C, Tsioufis K, Grassi G, Seravalle G, Coca A, Sierra C, Lurbe E, Stabouli S, Jelakovic B, Nilsson PMObesity and cardiovascular risk: a call for action from the European Society of Hypertension Working Group of Obesity, Diabetes and the High-risk Patient and European Association for the Study of Obesity: part A: mechanisms of obesity induced hypertension, diabetes and dyslipidemia and practice guidelines for treatment. J Hypertens. 2018 Jul;36(7):1427-1440. doi: 10.1097/HJH.0000000000001730.
187 Kotsis V, Tsioufis K, Antza C, Seravalle G, Coca A, Sierra C, Lurbe E, Stabouli S, Jelakovic B, Redon J, Redon P, Nilsson PM, Jordan J, Micic D, Finer N, Leitner DR, Toplak H, Tokgozoglu L, Athyros V, Elisaf M, Filippatos TD, Grassi G. Obesity and cardiovascular risk: a call for action from the European Society of Hypertension Working Group of Obesity, Diabetes and the High-risk Patient and European Association for the Study of Obesity: part B: obesity-induced cardiovascular disease, early prevention strategies and future research directions. J Hypertens. 2018 Jul;36(7):1441-1455. doi: 10.1097/HJH.0000000000001731.
188 Wade KH, Chiesa ST, Hughes AD, Chaturvedi N, Charakida M, Rapala A, Muthurangu V, Khan T, Finer N, Sattar N, Howe LD, Fraser A, Davey Smith G, Deanfield JE, Timpson NJ. Assessing the Causal Role of Body Mass Index on Cardiovascular Health in Young Adults: Mendelian Randomization and Recall-by-Genotype Analyses. Circulation. 2018 Nov 13;138(20):2187-2201. doi: 10.1161/CIRCULATIONAHA.117.033278. Epub 2018 Jul 30.
189 Charakida M, Georgiopoulos G, Dangardt F, Chiesa ST, Hughes AD, Rapala A, Davey Smith G, Lawlor D, Finer N, Deanfield JE. Early vascular damage from smoking and alcohol in teenage years: the ALSPAC study. Eur Heart J. 2019 Jan 21;40(4):345-353. doi: 10.1093/eurheartj/ehy524.
190 Brackenridge L, Finer N, Batterham RL, Pedram K, Ding T, Stephenson J, Barry J, Hardiman P. Pre-pregnancy weight loss in women with obesity requesting removal of their intra-uterine contraceptive device in order to conceive: a pilot study of full meal replacement. Clin Obes. 2018 Aug;8(4):244-249. doi: 10.1111/cob.12252. Epub 2018 Jun 11.
191 Suvan JE, Finer N, D'Aiuto F. Periodontal complications with obesity. Periodontol 2000. 2018 Oct;78(1):98-128. doi:10.1111/prd.12239. Review.
192 Finer N. Letter to the Editor regarding Mocanu et al. Ongoing Inconsistencies in Weight Loss Reporting Following Bariatric Surgery: A Systematic Review. Obesity Surgery https://doi.org/10.1007/s11695-018-03702-6Mocanu. Obes Surg. 2019 Mar 16. doi: 10.1007/s11695-019-03827-2
193 Dangardt F, Charakida M, Georgiopoulos G, Chiesa ST, Rapala A, Wade KH, Hughes AD, Timpson NJ, Pateras K, Finer N, Sattar N, Davey Smith G, Lawlor DA, Deanfield JE. Association between fat mass through adolescence and arterial stiffness: a population-based study from The Avon Longitudinal Study of Parents and Children. Lancet Child Adolesc Health. 2019 Jul;3(7):474-481. doi: 10.1016/S2352-4642(19)30105-1. Epub 2019 May 21.194
194 Finer N. Weight loss for patients with obesity and heart failure. Eur Heart J. 2019 Jul 1;40(26):2139-2141. doi: 10.1093/eurheartj/ehz406.
195 Finer N, Garnett SP, Bruun JM. COVID-19 and obesity. Clin Obes. 2020Jun;10(3): e12365. doi: 10.1111/cob.12365. Epub 2020 Apr 27.
196 Reges O, Leibowitz M, Hirsch A, Dicker D, Finer N, Haase CL, Satylganova A, Leventer-Roberts M, Feldman B. A comprehensive descriptive assessment of obesity related chronic morbidity and estimated annual cost burden from a population-based electronic health record database. Isr J Health Policy Res. 2020 Jun 24;9(1):32. doi: 10.1186/s13584-020-00378-1.
197 Reges O, Dicker D, Haase CL, Finer N, Karpati T, Leibowitz M, Satylganova A, Feldman B. Body mass index trajectories among people with obesity and association with mortality: Evidence from a large Israeli database. Obes Sci Pract. 2020 Dec 23;7(2):148-158. doi: 10.1002/osp4.475. PMID: 33841884; PMCID: PMC8019279.
198 Finer N. Future directions in obesity pharmacotherapy. Eur J Intern Med. 2021 Nov;93:13-20. doi: 10.1016/j.ejim.2021.04.024. Epub 2021 May 21. PMID: 34024701.
199 Finer N. Weight loss interventions and nonalcoholic fatty liver disease: Optimizing liver outcomes. Diabetes Obes Metab. 2022 Feb;24 Suppl 2:44-54. doi: 10.1111/dom.14569. Epub 2021 Oct 24. PMID: 34622555.
200 Dorthe S, Finer N, Friedrichsen MH, Hjerpsted JB, Engelmann MDM. Prevalence of Baseline Cardiac Arrhythmias in Participants with Overweight or Obesity in Phase 1 Clinical Trials: Analysis of 24-Hour Holter Electrocardiogram Recordings. Clin Pharmacol. 2023 May;63(5):539-543. doi: 10.1002/jcph.2193. Epub 2023 Jan 20.
201 Sharma AM, Birney S, Crotty M, Finer N, Segal-Lieberman G, Vázquez-Velázquez V, Vrijens B. Determinants of adherence to obesity medication: A narrative review. Obes Rev. 2025 May;26(5):e13885. doi: 10.1111/obr.13885. Epub 2025 Jan 20. PMID: 39832779; PMCID: PMC11964794.
202 By-Band-Sleeve Collaborative Group. Roux-en-Y gastric bypass, adjustable gastric banding, or sleeve gastrectomy for severe obesity (By-Band-Sleeve): a multicentre, open label, three-group, randomised controlled trial. Lancet Diabetes Endocrinol. 2025 Mar 31:S2213-8587(25)00025-7. doi: 10.1016/S2213-8587(25)00025-7. Epub ahead of print. PMID: 40179925.
Books
1 Finer N. Clinician’s guide to obesity. Hodder Arnold, London. ISBN: 0412754800
2 Finer N. Scientific Editor. Obesity, British Medical Bulletin 53(2), RSM Press, London 1997
3 Antel J, Heal D, Finer N Obesity and Metabolic Disorders. Solvay Pharmaceuticals Conferences. IOS Press, Amsterdam, 2005
4 An Expert Guide to Weight Loss Surgery for Primary Care. Eds: Haslam D and Finer N. London Science and 2015.
5 Sbraccia P and Finer N. Obesity, Pathogenesis, diagnosis and treatment. Springer Reference. Endocrinology: series editor Lenzi, A. Springer 2019.
Chapters in Books
1 Finer N. Health Consequences of Obesity.
In: Proceedings of the Symposium on Low Calorie Products; Ed Birch GG & Lindley MG. Elsevier Applied Science Publications, 1988.
2 Finer N. Are sweeteners really useful to diabetics?
In: Advances in Sweeteners; Ed Grenby T. Elsevier Applied Science Publications, 1989.
3 Finer N. Sweeteners and Metabolic Disorders.
In: A Handbook of Sweeteners; Ed Marie S and Piggot JR. Blackie and Son, Glasgow, 1991.
4 Cooper JR, Kupshik GA, Finer N. Mood Related Eating is not Carbohydrate Craving.
In: Obesity in Europe 1993; Ed Ditschuneit H, Gries FA, Hauner H et al. J Libbey & Co Ltd,1994.
5 Finer N. Eating for Health - Nutrition in the 1990’s. In: European Union of General Practitioners Reference Book 1994/5. Ed N Ellis Kensington Publications Ltd, 1994.
6 Finer N. Energy Metabolism and Obesity. In: Modules in Life Sciences. Molecular Pathology; Ed J Salisbury, Taylor and Francis, London 1997
7 Finer N. Present and future pharmacological approaches. In: Obesity, Ed. N Finer British Medical Bulletin 53(2), RSM Press, London 1997
8 Finer N. Weight management approaches. In: Encyclopaedia of Human Nutrition. Eds. Sadler M, Caballero B, Strain S. Academic Press 1998.
9 Finer N. Clinical assessment: investigation and principles of management - realistic weight goals. In: Clinical Obesity. Eds. Kopelman PG and Stock M. Blackwell Science, Oxford.1998.
10 Finer N, Prentice A. Aetiology of obesity: endocrine causes. In: Obesity. Report of the British Nutrition Task Force. Blackwell Science 1999.
11 Finer N. Medical Management of Obesity. In: Horizons in Medicine 12. Ed Weissberg P. Royal College of Physicians London 2000
12 Finer N. Pharmacotherapy of obesity.
Best Pract Res Clin Endocrinol Metab. 2002 Dec;16(4):717-42
13 Finer N. Obesity and Metabolic Disorders. Solvay Pharmaceuticals Conferences. IOS Press, Amsterdam 2005
14 N. Finer. Medical consequences of obesity. Review Article
Medicine, Volume 34, Issue 12, December 2006, Pages 510-514
15 Lean M and Finer N. Management Pt II: Drugs. In: ABC of Obesity. Eds.: Sattar N and Lean M. Blackwell BMJ Books. 2007
16 Caterson I, Baur L, Finer N. Obesity Treatment for adults, adolescents and children. In A modern epidemic: expert perspectives on obesity and diabetes (Eds. Baur LA, Twigg SM, Magnusson RS). Sydney University Press 2012.
17 N. Finer. Weight Management: Approaches. Encyclopaedia of Human Nutrition (Third Edition), 2013, Pages 404-409
18 Finer N. Obesity. In Oxford Handbook of Endocrinology and Diabetes. 3rd Edition. Eds: J Wass, K Owen. Oxford University Press, Oxford, England 2014.
19 A Pucci & N Finer. Commentary – Acute Medical Aspects related to Obesity. Endocrine and Metabolic Medical Emergencies. Endocrine Press (Ed. Matfin G).2014.
20 Finer N. Medical consequences of Obesity. In Medicine. Elsevier Medicine Publishing. 2015
21 Haslam D and Finer N. An expert guide to weight loss surgery for primary care. London, England 2015.
22 Finer N. Defining the role of Metabolic Physician. In: Clinical Dilemmas in Non-Alcoholic
Fatty Liver Disease (Eds. Williams R and Taylor-Robinson S. Wiley-Blackwell 2016
23 Finer N. Chapter 15.2: Obesity. In: Oxford Desk Reference: Endocrinology (Eds Helen E. Turner, Richard Eastell, and Ashley Grossman). OUP, Oxford, July 2018. ISBN: 978019967283
24 Finer N. 14.1.8 Planning Obesity Care Pathways. In: Oxford Textbook of Endocrinology and Diabetes. 3rd Ed. Editors Wass, Arlt & Semple. Oxford University Press 2022.
25 Finer N. Obesity and Diabetes. In: Textbook of Diabetes (Eds. Holt R, Flyvbjerg A) J Wiley 2014.
Offline Website Maker